883901-62-0

Basic information

• Product Name: 1-Azetidinecarboxylic acid, 3-(4-nitrophenyl)-, 1,1-dimethylethyl ester
• CAS NO: 883901-62-0
• Molecular Formula: C14H18N2O4
• Molecular Weight: 278.308
• Mol File: 883901-62-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Azetidinecarboxylic acid, 3-(4-nitrophenyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Azetidinecarboxylic acid, 3-(4-nitrophenyl)-, 1,1-dimethylethyl ester(883901-62-0)
• EPA Substance Registry System: 1-Azetidinecarboxylic acid, 3-(4-nitrophenyl)-, 1,1-dimethylethyl ester(883901-62-0)

Safety Data

• Hazardous Substances Data: 883901-62-0(Hazardous Substances Data)

Usage

Molecular Weight

254.25 g/mol

Structure

A derivative of 1-azetidinecarboxylic acid with a 4-nitrophenyl group attached at the 3-position and a 1,1-dimethylethyl ester group at the 1-position.

Appearance

Likely a solid or crystalline substance, though specific appearance is not provided.

Potential Applications

Organic synthesis, drug development, pharmaceuticals, and agrochemicals.

Reactivity

Commonly used as a reagent in chemical reactions.

Stability

Enhanced stability due to the 1,1-dimethylethyl ester group.

Handling

Should be handled with care and in accordance with proper safety guidelines.

Storage

Requires appropriate storage conditions to maintain stability and prevent degradation.

Safety Precautions

Not explicitly mentioned, but generally, care should be taken to avoid contact with skin, eyes, and inhalation. Use in a well-ventilated area and follow relevant safety guidelines for chemical handling and disposal.

Upstream product

• 636-98-6 p-nitrobenzene iodide 
• 254454-54-1 tert-butyl-3-iodoazetidine-1-carboxylate 

Downstream Products

• 1566584-14-2 2-(2-(2-(2-((4-(azetidin-3-yl)phenyl)amino)-5-methylpyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1566585-32-7 tert-butyl 3-(4-((4-(2-(2-amino-2-oxoethyl)phenethyl)-5-methylpyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566584-02-8 2-(2-(2-(2-((4-(azetidine-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1566584-92-6 tert-butyl 3-(4-((4-(2-(2-amino-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566584-91-5 2-(2-(2-(2-((4-(1-(tert-butoxycarbonyl)azetidine-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetic acid 
• 1566584-90-4 tert-butyl 3-(4-((4-(2-(2-methoxy-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566584-89-1 tert-butyl 3-(4-((4-((2-(2-methoxy-2-oxoethyl)phenyl)ethynyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566543-78-9 tert-butyl 3-(4-((4-(2-(1-(methoxycarbonyl)cyclopropyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566542-79-7 1-(2-(2-(2-((4-(azetidin-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)cyclopropanecarboxamide 
• 1566543-79-0 tert-butyl 3-(4-((4-(2-(1-carbamoylcyclopropyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566543-77-8 tert-butyl 3-(4-((4-((2-(1-(methoxycarbonyl)cyclopropyl)phenyl)ethynyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 916421-36-8 tert-butyl 3-(4-aminophenyl) azetidine-1-carboxylate 
• 1566543-57-4 tert-butyl 3-(4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidi ne-1-carboxylate 

Relevant articles and documents

VEGFR3 INHIBITORS

This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for th

HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR

The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, Cl-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6- alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1 -C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- -membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.